A carregar...
Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA‐REG OUTCOME(®) trial
AIMS/INTRODUCTION: In the EMPA‐REG OUTCOME(®) trial, empagliflozin added to standard of care improved clinically relevant kidney outcomes by 39%, slowed progression of chronic kidney disease, and reduced albuminuria in patients with type 2 diabetes and established cardiovascular disease. This explor...
Na minha lista:
| Publicado no: | J Diabetes Investig |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6497612/ https://ncbi.nlm.nih.gov/pubmed/30412655 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdi.12971 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|